News Release Detail
April 2, 2004
Mylan Responds to Alza's Letter to the FDA on Fentanyl
Mylan Responds to Alza's Letter to the FDA on Fentanyl
Mylan Responds to Alza's Letter to the FDA on FentanylPITTSBURGH--(BUSINESS WIRE)--April 2, 2004--Mylan Laboratories
Inc. (NYSE: MYL) announced that correspondence was submitted to the
FDA today on its behalf with regard to its transdermal fentanyl
product. Mylan's letter is a response to the March 31, 2004 letter
submitted by Alza Corporation, a subsidiary of Johnson & Johnson.
Copies of the correspondence have been filed with a Form 8-K and will
be accessible on the SEC's website at www.sec.gov.
Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.
For more information about Mylan, visit www.mylan.com.
CONTACT: Mylan Laboratories Inc. Kris King, 724-514-1800 SOURCE: Mylan Laboratories Inc.